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Conclusions: The intra-articular injections of autologous PRP showed a
reduction of pain, symptoms and a recover articular function in patients
affected by severe chondropaties of the knee. The patients 45 years old,
males, and without osteoarthritis showed a faster clinical improvement.
283 PATIENT RELEVANT OUTCOME 7 YEARS AFTER TOTAL HIP
REPLACEMENT FOR OA – A PROSPECTIVE STUDY
A.K. Nilsdotter1, S.L. Lohmander2. 1Department of Orthopedics,
Halmstad, SWEDEN, 2Department of Orthopedics, Clinical Sciences
Lund, Lund University, SWEDEN
Purpose: To investigate prospectively the patient-relevant outcome
7 years after total hip replacement (THR) for osteoarthritis (OA).
Methods: 219 consecutive patients (120 women) with primary OA, mean
age 71 (range 50−92) were assigned for THR at the Department of
Orthopedics at Halmstad Central Hospital, Sweden. They were examined
preoperatively, at 3, 6, 12 months, and at 4, 5 and 7 years postoper-
atively with the self-administered questionnaires SF-36 and WOMAC.
Supplementary questions regarding postoperative complications, general
co-morbidity, social circumstances and patient satisfaction were asked
at the three last follow-ups. A matched reference group, 117 subjects
(67 women), mean age 72 (range 52−92) without hip complaints were
recruited from the community and investigated at the same times.
Results: 151/170 (89%) of the patients and 65/74 (88%) of the reference
group participated at the 7 year follow-up. The best postoperative result
was reported one year postoperatively. At that time the only difference
between the two groups was seen in SF-36 physical function (PF), where
the patients scored worse than the reference group (54 vs. 69). At the
later follow-ups there was a successive decline in SF-36 PF compared
to the reference group. However, patients did not report worse WOMAC
function than the reference group. There was no difference in frequency
of co-morbid conditions (19% vs. 31% p< 0.08) between those operated
and the reference group, but those operated were in greater need of
walking aid (46% vs.8% p< 0.0001) and reported more regional pain and
widespread pain (68% vs. 53% p< 0.05). However, 97% of the patients
were satisﬁed with pain relief and 96% with improved physical function
at the 7 year follow-up.
Conclusions: Total hip replacement for osteoarthritis is a successful
procedure. This study shows that in an unselected cohort the patients
experience the same health-related quality of life as a matched reference
group 7 years after THR except for physical function where the patients
score worse. This may be explained by musculoskeletal co-morbidities
such as progress in generalized OA. The difference in outcome between
SF-36 PF and WOMAC function may be explained by the disparity
between a generic and a disease and extremity speciﬁc measurement
where SF-36 PF represents the entire physical function.
284 AN ORAL RECOMBINANT FORM OF SALMON CALCITONIN
SUPPRESSES BOTH BONE RESORPTION AND CARTILAGE
DEGRADATION
I. Byrjalsen, K. Henriksen, B.J. Riis, M.A. Karsdal, C. Christiansen.
Nordic Bioscience, Herlev, DENMARK
Purpose: Calcitonin suppresses bone resorption, and appears to have
an effect on cartilage degradation, and therefore has been speculated to
be useful for treatment of osteoarthritis. However, the pharmacodynamic
proﬁle of sCT on cartilage degradation is not clear. The aim of the study
was to assess the effect of bi-daily dosing with 0.8mg of oral salmon
calcitonin (sCT) given in the morning at 08:00 and pre-dinner at 17:00
with respect to reduction of both bone resorption (CTX-I) and cartilage
degradation (CTX-II).
Methods: Participants were from a randomized, double-blind, placebo-
controlled 14-day treatment study including postmenopausal women and
men (n=73) suffering from osteoarthritis (OA). One of the treatment arms
comprised administration of 0.8mg of oral sCT given twice daily with one
dose given in the morning to fasting individuals at 08:00, and one dose
given pre-dinner at 17:00 (n=26). On treatment day 1 and day 14, blood
samples were taken before drug intake, and at 10, 15, 30, 45 minutes,
and 1, 2, and 4 hours for plasma sCT measurements. Urine samples were
collected at baseline, at 2, 4, 6, 8, 11 and 13 hours. The absorption of
calcitonin was assessed by measurement of plasma sCT concentrations,
and bone resorption by the biochemical marker of urine CTX-I (C-terminal
telopeptide of collagen type I). Cartilage degradation was assessed by
urine CTX-II (C-terminal telopeptide of collagen type II).
Results: Dosing with oral sCT resulted in a signiﬁcant increase in
plasma sCT levels, which was eliminated within two hours after dosing. In
alignment, urine CTX-I was suppressed over placebo with an AUC0−8hrs of
−425 [%×Hrs] at the 8:00 dose compared to −105 [%Hrs] in the placebo
group (p = 0.003). The suppression of CTX-I was present throughout the
13 hours sampling period. For CTX-II a suppression of the AUC0−8hrs
of −355 [%Hrs] was observed compared to −60 [%Hrs] in the placebo
group (p< 0.007). The suppression of CTX-II was not alleviated within
the 13 hour observation period. The results from the day 14 analysis
were all in the same magnitude.
Conclusions: We found that an oral recombinant form of salmon calci-
tonin signiﬁcantly suppressed both bone resorption and cartilage degra-
dation within a short time span. These studies warrant further investiga-
tion of the potential use of oral calcitonin for treatment of osteoarthritis.
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ASPECTS OF EROSIVE OSTEOARTHRITIS (EOA) OF THE
HAND IN A GROUP OF PATIENTS FOLLOWED FOR 2 YEARS
FROM A SINGLE CENTER
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ITALY , 2Oncology Department, University of Padova, Padova, ITALY,
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Purpose: EOA is believed to be a clinical subset of OA most often
involving the hands of middle-aged women and characterised by a
frequent aggressive clinical course. In EOA, pain and inﬂammation persist
or recur for many years, in contrast with the more common nodal OA
(non-EOA), in which they are usually found only at the disease onset.
Despite its severity, EOA is still poorly deﬁned, so it is debated whether
or not it belongs to OA or is a separate entity. Since very few reports are
available concerning the various features of EOA, the aim of our study
was to analyse its clinical, radiological and immunogenetic aspects in a
cohort of 109 patients observed in our unit, and compare these with a
series of non-EOA patients
Methods: A total of 162 patients, 109 with EOA and 53 with non-EOA
were analysed. All patients satisﬁed the Altman criteria for OA of the hand.
Patients showing at least two erosions in interphalangeal (IP) joints were
included in EOA, while patients with erosions in metacarpophalangeal
joints were excluded. In all patients (EOA and non-EOA) we evaluated
the number of active joints (AJ) (swollen and painful), number of joints
involved (NJI) and the radiographic score (RS) by Kallman scale. In
24 patients with EOA followed for at least two years, we evaluated the
outcome for clinical and radiological aspects. Patients underwent hand
X-rays at the baseline and after a two year period and assessment was
done by two experienced operators. The clinical examination was also
performed at the ﬁrst visit and after two years. In all patients HLA typing
was determinated on blood samples (GenoPrepTM DNA from Blood Kit
by GenoVision A.S, Norway; PCR Master Mixes).
Results: No difference was observed between EOA and non-EOA for age
and disease duration. The mean number of erosions in EOA was 4.01
(±2.4). Both the number of AJ and the RS were higher in EOA (6.3±2.4
and 65.9±26.5, respectively) than in non-EOA (4.5±4.6, p = 0.02 and
32.1±19.1, p< 0.001, respectively).
In the subset of 24 patients with highest RS at baseline and more severe
joint involvement, we observed a signiﬁcant worsening in both radiological
and clinical parameters (RS at baseline vs two years p< 0.001; NJI vs
NJI2 p< 0.001; AJ vs AJ2 p< 0.012). Concerning HLA, in this subgroup
of patients we observed higher frequency of the allele A24 (29.1%), A2
(45.8%), DRB1 11 (37.5%), DRB 07 (16.6%).
Conclusions: EOA clearly differs from non-EOA in many aspects, in-
cluding the higher AJ and RS, so conﬁrming its severity. We observed a
more aggressive clinical course in the subgroup of patients who presented
higher scores at the ﬁrst visit. The association with some HLA alleles, in
particular A2, A24, DRB 07 and 11, suggests a more severe subset of
patients. Further studies are needed to conﬁrm these data.
286 DIFFUSE IDIOPATHIC SKELETAL HYPEROSTOSIS (DISH) AT,
OR BEFORE, THE FIFTH DECADE OF LIFE
R. Mader1, I. Lavi2. 1Ha’Emek Medical Center, Afula, ISRAEL, 2Carmel
Medical Center, Haifa, ISRAEL
Purpose: At present, the diagnosis of DISH is based on characteristic
ﬁnding in radiographs of the thoracic spine, which are not often ordered.
